title: Global clinical trials for the treatment of TB with thioridazine.
abstract: Current evidence shows that thioridazine (THZ) is ready for global clinical evaluation, while some of its derivatives and other efflux pump inhibitors reach the end stage of preclinical evaluation. In this paper, a clinical trial plan is described that investigates the antituberculosis potency, the safety profile and the role of THZ and/or its derivatives in the treatment of TB in humans, both in patients infected with drug sensitive strains as in patients infected with multi or extensive drug resistant strains of Mycobacterium tuberculosis and some of the patents related to thioridazine are also discussed.
authors.affiliation: Radboud University Nijmegen Medical Centre, University Centre for Chronic Disease Dekkerswald, Nijmegen, the Netherlands. m.boeree@uccz.umcn.nl
authors.forename: Martin J
authors.initials: MJ
authors.lastname: Boeree
mesh_terms: D000995:Antitubercular Agents / Q000009:adverse effects / Q000627:therapeutic use*; D002986:Clinical Trials as Topic; D055808:Drug Discovery; D024901:Drug Resistance, Multiple, Bacterial; D004359:Drug Therapy, Combination; D019317:Evidence-Based Medicine; D054908:Extensively Drug-Resistant Tuberculosis / Q000188:drug therapy* / Q000382:microbiology; D006801:Humans; D009169:Mycobacterium tuberculosis / Q000187:drug effects* / Q000472:pathogenicity; D010330:Patents as Topic; D018570:Risk Assessment; D013881:Thioridazine / Q000009:adverse effects / Q000627:therapeutic use*; D016896:Treatment Outcome; D018088:Tuberculosis, Multidrug-Resistant / Q000188:drug therapy* / Q000382:microbiology
chemical_list: D000995:Antitubercular Agents; D013881:Thioridazine